Status: Recruiting
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Merida BiosciencesUpdated: Jul 1, 2026Locations: 9
Eligibility criteria
Adults 18 to 65 years of age, inclusive, at the time of signing the ICF [+7]
total thyroidectomy. [+32]